Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947613 | 0.98 | GPR119 (0.51) | GPR119CCNT1CDK9ENPP2CYP4F2 | |
| SCHEMBL982440 | 0.96 | GPR119 (0.54) | GPR119CCNT1CDK9ENPP2CYP4F2 | |
| SCHEMBL979614 | 0.86 | GPR119 (0.40) | GPR119CCNT1CDK9CYP4F2CYP4A11 | |
| SCHEMBL981851 | 0.85 | GPR119 (0.60) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL979908 | 0.83 | CCNT1 (0.39) | GPR119CCNT1CDK9ENPP2CYP4F2 | |
| SCHEMBL980833 | 0.83 | CCNT1 (0.39) | GPR119CCNT1CDK9ENPP2CYP4F2 | |
| SCHEMBL15540108 | 0.82 | GPR119 (0.47) | GPR119 | |
| SCHEMBL10040266 | 0.82 | CCNT1 (0.41) | CCNT1CDK9CYP4F2CYP4A11 | |
| SCHEMBL977156 | 0.81 | GPR119 (0.51) | GPR119CCNT1CDK9ENPP2LMNA | |
| SCHEMBL10040264 | 0.81 | CCNT1 (0.40) | GPR119CCNT1CDK9CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| WO-2011008663-A1 | GPR119 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015199-A1 | GPR119 Agonists | GPR119, GLP1R, GCGR | GPR119 1/4885CCNT1 4475/4885CDK9 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.